Enlivex Therapeutics Ltd
1BT
Company Profile
Business description
Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.
Contact
14 Einstein Street
Ness Ziona7403618
ISRT: +972 26208072
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
36
Stocks News & Analysis
stocks
Cheapest ASX member of our Best Idea’s list
This share is trading at the lowest price to fair value of the 14 companies on the list.
stocks
We remove our Moat Rating from ASX listed share
Despite a surging share price a weakening competitive position causes a reassessment of our view.
stocks
Best sustainable companies to own in 2026
We believe these companies’ strong ESG management practices give them a long-term advantage.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,996.90 | 37.80 | -0.42% |
| CAC 40 | 8,237.43 | 25.93 | 0.32% |
| DAX 40 | 24,892.20 | 23.51 | 0.09% |
| Dow JONES (US) | 49,367.96 | 390.78 | 0.80% |
| FTSE 100 | 10,122.73 | 118.16 | 1.18% |
| HKSE | 26,710.45 | 363.21 | 1.38% |
| NASDAQ | 23,498.38 | 102.56 | 0.44% |
| Nikkei 225 | 52,518.08 | 685.28 | 1.32% |
| NZX 50 Index | 13,663.58 | 76.35 | 0.56% |
| S&P 500 | 6,933.53 | 31.48 | 0.46% |
| S&P/ASX 200 | 8,682.80 | 45.80 | -0.52% |
| SSE Composite Index | 4,083.67 | 60.25 | 1.50% |